ENCARNACIÓN GONZÁLEZ RODRÍGUEZ-rekin lankidetzan egindako argitalpenak (66)

2024

  1. Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study

    Clinical and Translational Oncology

  2. Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 851-863

  3. Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia

    Clinical and Translational Oncology

  4. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 1

  5. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology

2023

  1. Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients

    Pharmaceutics, Vol. 15, Núm. 11

  2. Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

    Cancers, Vol. 15, Núm. 6

  3. Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis

    NMR in Biomedicine, Vol. 36, Núm. 9

2022

  1. Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 41, Núm. 4, pp. 231-238

  2. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Circulating ptgs2, jag1, gucy2c and pgf mrna in peripheral blood and serum as potential biomarkers for patients with metastatic colon cancer

    Journal of Clinical Medicine, Vol. 10, Núm. 11

  2. Controversies in the treatment of RAS wild-type metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839

  3. Deep phenotypic characterisation of CTCs by combination of microfluidic isolation (Isoflux) and imaging flow cytometry (imagestream)

    Cancers, Vol. 13, Núm. 24

  4. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  5. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

    ESMO open, Vol. 6, Núm. 4, pp. 100215

  6. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

    Clinical and Translational Oncology, Vol. 23, Núm. 8, pp. 1520-1528

2020

  1. Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 647-662

  2. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

  3. The polemic diagnostic role of TP53 mutations in liquid biopsies from breast, colon and lung cancers

    Cancers, Vol. 12, Núm. 11, pp. 1-17

2019

  1. Correction to: Recommendations for follow‑up of colorectal cancer survivors (Clinical and Translational Oncology, (2019), 21, 10, (1302-1311), 10.1007/s12094-019-02059-1)

    Clinical and Translational Oncology